PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Tumor heterogeneity is one of the greatest obstacles standing in the way of successful cancer therapy. Cancer in a single patient is not a single disease, but is a host of related diseases, all of which need to respond to a single treatment regimen. We have completed the first human clinical trial in esophageal cancer using dynamic-contrast OCT (DC-OCT) based on full-frame digital holography to assess the spatial heterogeneity of biopsy response to platinum-based chemotherapy. A deep twin neural network successfully identified biopsy sub-phenotypes in the dynamic tissue response that enabled accurate prediction of patient treatment success.
Zhen Hua,Shadia Jalal,John Turek, andDavid D. Nolte
"Classifying tumor heterogeneity of human esophageal cancer biopsies by dynamic contrast OCT with deep learning", Proc. SPIE 12367, Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XXVII, 123670L (8 March 2023); https://doi.org/10.1117/12.2647602
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Zhen Hua, Shadia Jalal, John Turek, David D. Nolte, "Classifying tumor heterogeneity of human esophageal cancer biopsies by dynamic contrast OCT with deep learning," Proc. SPIE 12367, Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XXVII, 123670L (8 March 2023); https://doi.org/10.1117/12.2647602